Krystal Biotech
KRYS
308.89
-6.93
-2.19%
Krystal Biotech
US · KRYS
#1515 by market cap
Listed 2017
308.89
-6.93
-2.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 20 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.9 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 100.46% -1.92pp
- Institutions
- 535 +20
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund74.57%
Hedge Fund17.36%
Individual/Insider9.93%
Public Company2.89%
VC/PE Fund2.15%
Private Company1.18%
Sovereign Wealth Fund0.89%
Government Pension Fund0.82%
Insurance Company0.35%
Top holders as of 2026-09-30
FMR
14.98% · 4.44M sh
BlackRock
12.12% · 3.59M sh
Avoro Capital Advisors LLC
9.75% · 2.89M sh
Suma Krishnan
4.87% · 1.44M sh
Krish Krishnan
4.81% · 1.43M sh
State Street Global Advisors
4.79% · 1.42M sh
Vanguard Portfolio Management, LLC
4.34% · 1.29M sh
Vanguard Capital Management, LLC
4.04% · 1.20M sh
Soleus Capital Management, L.P.
3.17% · 939.25K sh
Capital Research
2.63% · 777.84K sh
Geode Capital Management, LLC
2.74% · 811.74K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Suma Krishnan | Founder, President of R&D and Director | 4.87% |
| Krish Krishnan | Chairperson & CEO | 4.81% |
| Dino Rossi | Independent Director | 0.17% |
| Kathryn Romano | Chief Accounting Officer | 0.08% |
| Laurent Goux | Executive VP & Head of International | 0.00% |
| Daniel Janney | Lead Independent Director | -- |
| Julian Gangolli | Independent Director | -- |
| E. Sutherland | Independent Director | -- |
| Alta Bioequities | -- | -- |
| Christopher Mason | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | Dino Rossi | Independent Director | Other Disposition | -3,500 | -- |
| 2026-09-13 | Daniel Janney | Lead Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Daniel Janney | Lead Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Dino Rossi | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Dino Rossi | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Julian Gangolli | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Julian Gangolli | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | E. Sutherland | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | E. Sutherland | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Christopher Mason | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Christopher Mason | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Catherine Mazzacco | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Catherine Mazzacco | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-03 | Krish Krishnan | Chairperson & CEO | Automatic Disposition | -520 | $354.54 |
| 2026-09-03 | Krish Krishnan | Chairperson & CEO | Open Market Disposition | -24,480 | $355.57–366.56 |
| 2026-09-03 | Suma Krishnan | Founder, President of R&D and Director | Automatic Disposition | -520 | $354.54 |
| 2026-09-03 | Suma Krishnan | Founder, President of R&D and Director | Open Market Disposition | -24,480 | $355.57–366.56 |
| 2026-08-13 | Dino Rossi | Independent Director | Other Disposition | -3,691 | -- |
| 2026-08-13 | Dino Rossi | Independent Director | Open Market Disposition | -25,000 | $325.60–333.23 |
| 2026-06-24 | John Thomas | EVP, General Counsel & Corporate Secretary | Derivative Exercise and Sale | -1,000 | $179.25–347.27 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Krystal Biotech discussion 0 comments